Animal models of hemophilia.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Progress in Molecular Biology and Translational Science

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/B978-0-12-394596-9.00006-8PMID 22137432PMCID PMC3713797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.

  2011influential reference
• Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model.

  2011cited by this paper
• Immunoglobulin isotypes and functional anti‐FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice

  2011influential reference
• Hepatocyte-Targeted Expression by Integrase-Defective Lentiviral Vectors Induces Antigen-Specific Tolerance in Mice with Low Genotoxic Risk

  2011cited by this paper
• Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

  2011cited by this paper
• A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.

  2011cited by this paper
• Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

  2011cited by this paper
• In vivo genome editing restores hemostasis in a mouse model of hemophilia

  2011cited by this paper
• New Adeno-Associated Virus Strategies to Support Momentum in the Clinic

  2011cited by this paper
• Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

  2011cited by this paper
• Codon optimization of human factor VIII cDNAs leads to high-level expression.

  2011cited by this paper
• Gene therapy for haemophilia: a long and winding road

  2011cited by this paper
• Induction of tolerance to factor VIII by transient co‐administration with rapamycin

  2011cited by this paper
• In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.

  2011cited by this paper
• Long-term phenotypic correction in factor IX knockout mice by using phiC31 integrase-mediated gene therapy

  2011cited by this paper
• The expanding menagerie: animal models of hemophilia A

  2010cited by this paper
• Recombinant Factor IX for Clinical and Research Use

  2010cited by this paper
• Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.

  2010cited by this paper
• Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.

  2010cited by this paper
• Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.

  2010cited by this paper
• FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis

  2010cited by this paper
• Detection of factor IX gene mutations by high-resolution melting analysis

  2010cited by this paper
• Wound healing in haemophilia – breaking the vicious cycle

  2010cited by this paper
• The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

  2010cited by this paper
• Preclinical and clinical progress in hemophilia gene therapy

  2010cited by this paper
• Gene therapy for immunological tolerance: using ‘transgenic’ B cells to treat inhibitor formation

  2010cited by this paper
• Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

  2010cited by this paper
• Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B

  2010cited by this paper
• High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.

  2010cited by this paper
• Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol

  2010cited by this paper
• WAG‐F8m1Ycb rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A

  2010cited by this paper
• Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

  2010cited by this paper
• Hemophilia: new protein therapeutics.

  2010cited by this paper
• Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

  2010cited by this paper
• Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia B. WFH State‐of‐the‐Art Session on Therapeutic Gene Transfer Buenos Aires, Argentina

  2010cited by this paper
• Hemophilic synovitis: factor VII and the potential role of extravascular factor VIIa.

  2010cited by this paper
• Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B

  2010cited by this paper
• Prolonged activity of factor IX as a monomeric Fc fusion protein.

  2010cited by this paper
• Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice

  2010influential reference
• Spontaneous coagulopathy in inbred WAG/RijYcb rats.

  2010cited by this paper
• Generation of a novel factor IX with augmented clotting activities in vitro and in vivo

  2010cited by this paper
• Clinical and molecular characterization of a re‐established line of sheep exhibiting hemophilia A

  2010cited by this paper
• Towards a standardization of the murine tail bleeding model

  2010influential reference
• De Novo Synthesis & Storage of Human Factor VIII In Platelets Reduces Bleeding In Canine Hemophilia A

  2010cited by this paper
• Prophylactic immune tolerance induced by changing the ratio of antigen‐specific effector to regulatory T cells

  2009cited by this paper
• Is VIII worse than IX?

  2009cited by this paper
• Opportunities and limitations of mouse models humanized for HLA class II antigens

  2009cited by this paper
• Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model.

  2009influential reference
• Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV

  2009cited by this paper
• Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.

  2009influential reference
• Factor VIII-Fc Fusion Protein Shows Extended Half-Life and Hemostatic Activity in Hemophilia A Dogs.

  2009cited by this paper
• Cytotoxic-T-Lymphocyte-Mediated Elimination of Target Cells Transduced with Engineered Adeno-Associated Virus Type 2 Vector In Vivo

  2009cited by this paper
• Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Index of Gene Therapy Vectors for Hemophilia B

  2009cited by this paper
• The secondary bleeding time; a new method for the differentiation of hemorrhagic diseases.

  2009cited by this paper
• Inhibitors of factor VIII in black patients with hemophilia.

  2009cited by this paper
• Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells

  2009cited by this paper
• Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.

  2009cited by this paper
• Inhibitors of factor VIII in hemophilia.

  2009cited by this paper
• Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.

  2009cited by this paper
• Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.

  2009cited by this paper
• Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

  2009cited by this paper
• Successful treatment of canine hemophilia by continuous expression of canine FVIIa.

  2009cited by this paper
• Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.

  2009cited by this paper
• Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

  2009cited by this paper
• CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.

  2009cited by this paper
• Inhibitors of factor VIII in hemophilia.

  2009cited by this paper
• The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice

  2009cited by this paper
• Enhancement of haemostatic efficacy of plasma‐derived FVIII by formulation with PEGylated liposomes

  2009cited by this paper
• Gene Therapy for Hemophilia: Clinical Trials and Technical Tribulations

  2009cited by this paper
• Cellular immune response to cryptic epitopes during therapeutic gene transfer

  2009cited by this paper
• Visualizing the Molecular and Cellular Basis of Heparin Induced Thrombocytopenia.

  2009cited by this paper
• Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.

  2008cited by this paper
• Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.

  2008cited by this paper
• Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer

  2008cited by this paper
• Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.

  2008cited by this paper
• Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.

  2008cited by this paper
• Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.

  2008cited by this paper
• A phase II prospective open‐label escalating dose trial of recombinant interleukin‐11 in mild von Willebrand disease

  2008cited by this paper
• Animal models of bleeding and tissue repair

  2008cited by this paper
• Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia.

  2008cited by this paper
• Successful in vivo propagation of factor IX-producing hepatocytes in mice: Potential for cell-based therapy in haemophilia B

  2008cited by this paper
• Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

  2008influential reference
• Complete Correction of Hemophilia A with Adeno-Associated Viral Vectors Containing a Full-Size Expression Cassette

  2008cited by this paper
• The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.

  2008cited by this paper
• Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.

  2008cited by this paper
• Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes

  2008cited by this paper
• Nicht-viraler Gentransfer führt zu therapeutischen Faktor-IX-Spiegeln im Hämophilie-B-Mausmodell

  2008cited by this paper
• [Non-viral gene transfer results in therapeutic factor IX levels in haemophilia B mice].

  2008cited by this paper
• Factor IX: Insights from knock-out and genetically engineered mice

  2008cited by this paper
• Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.

  2008cited by this paper
• American Society of Hematology annual meeting.

  2008cited by this paper
• Intrinsic Pathway of Coagulation and Arterial Thrombosis

  2007cited by this paper
• Ex Vivo Gene Therapy for Hemophilia A That Enhances Safe Delivery and Sustained In Vivo Factor VIII Expression from Lentivirally Engineered Endothelial Progenitors

  2007cited by this paper
• High expression reduces an antibody response after neonatal gene therapy with B domain‐deleted human factor VIII in mice

  2007cited by this paper
• A guide to murine platelet structure, function, assays, and genetic alterations

  2007cited by this paper
• Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice

  2007influential reference
• Cross-Presentation of Adeno-Associated Virus Serotype 2 Capsids Activates Cytotoxic T Cells But Does Not Render Hepatocytes Effective Cytolytic Targets

  2007cited by this paper
• Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.

  2007cited by this paper
• Lentivirus‐mediated platelet‐derived factor VIII gene therapy in murine haemophilia A

  2007cited by this paper
• In vivo thrombus formation

  2007cited by this paper

• Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression

  2026cites this paper
• Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review

  2026cites this paper
• Gene Therapy for Hemophilia - From Basic Science to First Approvals of "One-and-Done" Therapies.

  2025cites this paper
• Evaluation of discrepancy between clot-based and chromogenic factor IX coagulation assays in non-severe hemophilia B patients and identification of the causing mutations.

  2024cites this paper
• AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life

  2024cites this paper
• Generation of Mouse Model of Hemophilia A by Introducing Novel Mutations, Using CRISPR/Nickase Gene Targeting System

  2023cites this paper
• The Use of Embark in Teaching About Genetic Relatedness The Use of Embark in Teaching About Genetic Relatedness

  2022cites this paper
• Lifelong gene therapy in dogs with hemophilia A.

  2022cites this paper
• Long-term correction of haemophilia B through CRISPR/Cas9 induced homology-independent targeted integration.

  2022cites this paper
• Advances in Genome Editing and Application to the Generation of Genetically Modified Rat Models

  2021cites this paper
• Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants.

  2021cites this paper
• Gene Therapy:

  2021cites this paper
• Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A

  2021cites this paper
• Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration

  2021cites this paper
• Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors

  2020cites this paper
• Clinical Pathology of the Rat

  2020cites this paper
• The Immune Response to the fVIII Gene Therapy in Preclinical Models

  2020cites this paper
• Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A

  2020cites this paper
• Initial joint bleed volume in a delayed on‐demand treatment setup correlates with subsequent synovial changes in hemophilic mice

  2020cites this paper
• A Foundational Study for Normal F8-Containing Mouse Models for the miRNA Regulation of Hemophilia A: Identification and Analysis of Mouse miRNAs that Downregulate the Murine F8 Gene

  2020cites this paper
• Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing

  2020cites this paper
• Mouse models of hemostasis

  2020cites this paper
• CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs.

  2020cites this paper
• Clinical and laboratorial description of the differential diagnoses of hemostatic disorders in the horse.

  2020cites this paper
• Gene Therapy in Pediatric Liver Disease

  2019cites this paper
• Gene Therapy: Paving New Roads in the Treatment of Hemophilia

  2019cites this paper
• The national blueprint for future basic and translational research to understand factor VIII immunogenicity: NHLBI State of the Science Workshop on factor VIII inhibitors

  2019cites this paper
• Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs

  2019cites this paper
• Bleed volume of experimental knee haemarthrosis correlates with the subsequent degree of haemophilic arthropathy

  2019cites this paper
• Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.

  2018cites this paper
• Gene therapy for hemophilia: what does the future hold?

  2018cites this paper
• Category : Thrombosis and Hemostasis Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding Running title : Defective TAFI activation in hemophilia A

  2018cites this paper
• Advances in gene therapy for hemophilia: basis, current status, and future perspectives

  2018cites this paper
• Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models

  2017cites this paper
• Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test – Demonstrated in vitro and ex vivo

  2017cites this paper
• Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce

  2017cites this paper
• Lymphovenous hemostasis and the role of platelets in regulating lymphatic flow and lymphatic vessel maturation.

  2016cites this paper
• An Exon-Specific U1snRNA Induces a Robust Factor IX Activity in Mice Expressing Multiple Human FIX Splicing Mutants

  2016cites this paper
• Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies

  2016cites this paper
• Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

  2016cites this paper
• Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment

  2016cites this paper
• Adeno-associated viral vectors for the treatment of hemophilia.

  2016cites this paper
• Severe Hemophilia A in a Male Old English Sheep Dog with a C→T Transition that Created a Premature Stop Codon in Factor VIII.

  2016cites this paper
• Evaluation of the Immunomodulatory Activity of Hoslundia Opposita Vahl (Lamiaceae) Leaf Extract

  2016cites this paper
• Mini-review on "A novel one-step purification of mouse factor IX".

  2016cites this paper
• Treating Hemophilia by Gene Therapy

  2016cites this paper
• Neurofibromatosis type 1-associated brain tumors

  2016cites this paper
• Gene therapy for bleeding disorders

  2016cites this paper
• An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo.

  2015cites this paper
• Hepatic stellate cell-conditioned myeloid cells provide a novel therapy for prevention of factor VIII antibody formation in mice.

  2015cites this paper
• Individualizing prophylaxis in hemophilia: a review

  2015cites this paper
• Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.

  2015cites this paper
• Portal vein delivery of viral vectors for gene therapy for hemophilia.

  2014cites this paper
• Lessons Learned from Animal Models of Inherited Bleeding Disorders.

  2014cites this paper
• Progress and challenges in the development of a cell‐based therapy for hemophilia A

  2014cites this paper
• Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells.

  2014cites this paper
• Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.

  2014cites this paper
• A novel F8 −/− rat as a translational model of human hemophilia A

  2014cites this paper
• Factor IX Deficiency or Hemophilia B: Clinical Manifestations and Management

  2014cites this paper
• Suppression of Inhibitor Formation against Factor VIII in Hemophilia A Mice by Oral Delivery of Antigens Bioencapsulated in Plant Cells

  2014cites this paper
• Mutational analysis and coagulation factor VIII sequence in a colt with hemophila A by Elaine

  2013cites this paper
• Gene therapy: the promise of a permanent cure.

  2013cites this paper
• IL‐6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding‐induced arthropathy in hemophilia

  2013cites this paper
• In vitro and In vivo Model Systems for Hemophilia A Gene Therapy

  2013cites this paper
• Blood Clotting Factor VIII: From Evolution to Therapy

  2013cites this paper
• Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.

  2013cites this paper
• Muscle Gene Therapy for Hemophilia.

  2012cites this paper
• Inhibitory antibodies in hemophilia A

  2012cites this paper
• Les signaux de danger dans l'initiation de la réponse immunitaire contre le facteur VIII thérapeutique

  2012cites this paper
• ARFI ultrasound for in vivo monitoring of soft-tissue bleeding and hemostasis in a dog model of hemophilia

  2010cites this paper